Clinical Trials Directory

Trials / Completed

CompletedNCT06221696

Preventing Weight Regain Post-Semaglutide Treatment With Active Fiber Supplement (Soloways)

Preventing Weight Regain Post-Semaglutide Treatment With Active Fiber Supplement (Soloways): A Randomized, Placebo-Controlled, Double-Blind Clinical Trial

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
160 (actual)
Sponsor
S.LAB (SOLOWAYS) · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

This randomized, double-blind, placebo-controlled trial titled "Preventing Weight Regain Post-Semaglutide Treatment with Active Fiber Supplement (Soloways)" evaluated the efficacy of an active fiber supplement in preventing weight regain post-Semaglutide treatment. Participants were adults aged 18-65, with a history of obesity or overweight, and had completed a Semaglutide course. The study involved 160 participants, equally divided into two groups: one receiving the active fiber supplement (glucomannan, inulin, and psyllium) and the other a placebo, both taken 30 minutes before each main meal for 180 days. Co-primary endpoints were the percentage of weight regain from baseline to day 180 and metabolic health markers (blood glucose levels, HbA1c, lipid profile, blood pressure). Secondary endpoints included changes in BMI, body composition, and appetite assessment using VAS ratings and the Control of Eating Questionnaire (CoEQ). Participants also adhered to a reduced-calorie diet and increased physical activity, with all standard assays performed in a central laboratory. The study's objective was to determine the supplement's effectiveness in enhancing satiety, improving digestive health, and thus better managing weight compared to a placebo

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTActive Fiber Supplement GroupThree daily packets of active fiber supplement (each containing 1g of glucomannan, 1g of inulin, and 3g of psyllium), taken 30 minutes before each main meal. The supplement is provided by S.Lab (Soloways), LLC.
OTHERPlacebo GroupThree daily packets of placebo powder, taken 30 minutes before each main meal.

Timeline

Start date
2023-06-12
Primary completion
2023-11-23
Completion
2023-12-01
First posted
2024-01-24
Last updated
2024-02-13

Locations

1 site across 1 country: Russia

Source: ClinicalTrials.gov record NCT06221696. Inclusion in this directory is not an endorsement.